高危患者的降脂治疗策略__培训课件.pptVIP

* 到 * After 16 weeks follow-up, the primary end point measure (time to first occurrence of death, nonfatal acute MI, resuscitated cardiac arrest, or worsening angina with new objective evidence requiring urgent rehospitalization) occurred in 228?patients in the atorvastatin group (14.8%) and 269?patients in the placebo group (17.4%). Compared with placebo, atorvastatin treatment produced a significant (p=0.048) 16% reduction in the risk of the primary composite end point (95% confidence interval, 0.701–0.999) [15]. Reference 15. Data on file, Pfizer Inc. * A posthoc analysis of PROVE